|
 |
UltraseThis page contains recent news articles, when available, and an overview of Ultrase but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Ultrase (when available) Used in the treatment of cystic fibrosis or pancreatic dysfunction, pancrelipase helps improve fat digestion in the small intestine. Specifically, the lipase, protease and amylase components break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. Pancreatic enzymes are used to correct maldigestion, malabsorption and pain associated with pancreatic insufficiency. The major maldigestion/malabsorption problems arise from incomplete fat digestion. Exogenous pancrelipase reduces the amount of nitrogen and fat excreted in the stool. For treatment of cystic fibrosis, chronic pancreatitis, pancreatic duct blockage Mechanism Of Action: The lipase, protease and amylase components of pancrelipase break down fat, protein, and starches, respectively, in the small intestine. Lipase hydrolyzes fats into glycerol and fatty acids. Protease converts proteins into proteoses and derived substances, while amylase converts starches into dextrins and sugars. News Articles on Pancrelipase Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009 - Nov 5, 2009 Also contributing to the strong quarterly performance was continued growth in sales of partnered products, in particular ULTRASE® by Axcan and AMRIX® by ... CNNMoney.com (press release) Axcan results rise ahead of takeover - Jan 31, 2008 Its Ultrase pancreatic insufficiency treatment contributed $13.9 million, while Canasa, its treatment for active ulcerative proctitis, added $16.7 million. ... Reuters Canada Axcan Pharma Submits Complete New Drug Application for ULTRASE - Aug 2, 2007 MONT-SAINT-HILAIRE, QUEBEC--(Marketwire - Aug. 2, 2007) - Axcan Pharma Inc. ("Axcan" or the "Company") (TSX:AXP)(NASDAQ:AXCA) today announced that it has ... marketwire.com Axcan Pharma Sustains Growth in Fiscal 2007, With Record Revenue of … - Aug 9, 2007 The FDA has granted ULTRASE a Fast Track designation, which allows ... In addition, the ULTRASE NDA includes an intestinal perfusion study aimed at ... marketwire.com FDA Grants Fast Track-Status for Ultrase - Jun 25, 2007 Canadian pharmaceutical company Axcan announced that it has filed the chemistry, manufacturing and control data portion of its new drug application (NDA) ... FDA news - FDA news (subscription) Ultrase NDA preserves availability on regulated market. - May 19, 2008 Ultrase NDA preserves availability on regulated market. QUEBEC CITY -- In late April, the Food and Drug Administration was prepared to take pancreatic ... $9.94 - Drug Store News - Alacra Store Axcan Pharma Continues Solid Growth in Fiscal 2007, With Record … - May 10, 2007 ..."We also added momentum to our product pipeline by successfully launching PYLERA in the United States and finalizing the development of ULTRASE, ... ccnmatthews.com Press Release: Axcan Pharma Inc. Review in Progress. - M2 Presswire |... - Jun 22, 2007 New Drug Application For Ultrase Submitted - Revenue Guidance . ... Regulatory Filing for ULTRASE to be Initiated by the ... Overfill Formulation Axcan ... Pay-Per-View - M2 Presswire - HighBeam Research Axcan Pharma Inc. Review in Progress. - Jun 22, 2007 ..."We are committed to submitting a complete NDA filing for ULTRASE in the next ... Previous clinical Phase III studies confirmed that ULTRASE significantly ... Free with registration - M2 Presswire - AccessMyLibrary.com Loislaw Federal District Court Opinions - AXCAN SCANDIPHARM INC. v. … - Oct 19, 2007 Ultrase contains those needed enzymes and comes in three formulations — Ultrase ... In addition to Ultrase, there are two other major brand-name lines of ... Pay-Per-View - Loislaw Federal District Court Opinions - Loislaw Les profits d'Axcan Pharma bondissent de 27% - Jan 31, 2008 Canasa (proctite ulcéreuse) et Ultrase (maladies inflammatoires de l'intestin), mais aussi à une expansion des revenus de nos activités internationales» ... La Presse Affaires New York Miscellaneous Reports - O'MAHONY v. AXCAN … - Jun 18, 2008 This is a product liability action wherein the Plaintiff alleges serious personal injuries as a result of the ingestion of Ultrase MT 24 and MT 30, ... Pay-Per-View - New York Miscellaneous Reports - Loislaw Q4 2006 AXCAN PHARMA INC Earnings Conference Call - Part 2. - Dec 1, 2006 One of the things to realize if you look at the current pancreatic enzymes and so, also ULTRASE and VIOKASE the market is very satisfied with those products ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Q2 2006 AXCAN PHARMA INC Earnings Conference Call - Part 2. - May 5, 2006 The Ultrase sales that were reported were much higher than what would be justified by the prescription trends, has been running at about 10 million a ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Company Profile Report - Mar 22, 2008 Ultrase (Pancrelipase)/Ultrase MT (Pancrelipase); Viokase (Pancrelipase). Obstructed Ducts. Enzyme Replacement Therapy ... $50.00 - Revere Reports - Revere Axcan Scandipharm Inc. v. Ethex Corp., No. 07-2556 (D.Minn. 10/19/2007... - Oct 19, 2007 Ultrase contains those needed enzymes and comes in three formulations ... Ultrase . . . . That, however, is a matter that falls squarely within the primary ... $2.95 - U.S. District Court, District of... - VersusLaw Event Brief of Q2 2007 AXCAN PHARMA INC Earnings Conference Call - … - May 11, 2007 Finalizing the development of pancreatic enzyme ULTRASE, which has zero-overfill, a highly stable ... For all of the US products except ULTRASE, the price i. Free with registration - Fair Disclosure Wire - AccessMyLibrary.com Axcan Pharma Continues its Solid Growth Trend, Closing Fiscal 2007 … - Nov 29, 2007 Axcan completed the clinical trial program and produced the CMC (Chemistry, Manufacturing and Control) Data required for its NDA for ULTRASE and submitted ... marketwire.com Axcan Announces Record Revenue of .8 Million for the Second Quarter... - May 4, 2006 Additional studies on ULTRASE are currently carried on and anticipated to be completed and results submitted along with other clinical and Chemistry, ... RedOrbit Event Brief of Q1 2007 AXCAN PHARMA INC Earnings Conference Call - … - Feb 9, 2007 ULTRASE: 1. There was more competition in the pancreatic enzyme market. 2. AXCA was going to reprioritize ULTRASE into the P1 position as it moved into the ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Healthpoint, Ltd. v. Allen Pharmaceutical, LLC, No. SA-07-CA-0526-XR... - Mar 18, 2008 Rather, Axcan asserts that, by advertising their drugs as 'generic equivalents to' or 'substitutes for' Ultrase, the Defendants have engaged in false ... $2.95 - U.S. District Court, Western District... - VersusLaw Q3 2006 AXCAN PHARMA INC Earnings Conference Call - Part 2. - Aug 11, 2006 On ULTRASE and VIOKASE, can you maybe elaborate on what's the nature of this ... PRAKASH GOWD: Is there a new formulation of ULTRASE that is being tested? ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Axcan Pharma poursuit sa solide croissance au cours de l'exercice... - May 10, 2007 Axcan progresse actuellement en vue de finaliser sa présentation de drogue nouvelle ("PDN") sur ULTRASE et prévoit débuter les soumissions réglementaires ... ccnmatthews.com DEAR PHARMACIST, Don't blame the bird for feeling sleepy - Dec 6, 2005 Other popular brand names are Ultrase, Creon and Viokase. I should mention that digestive enzymes of all sorts are sold over the counter for people with ... Pay-Per-View - Newsday - ProQuest Archiver DEAR PHARMACIST SUZY COHEN - Dec 1, 2005 Other popular brand names are Ultrase, Creon and Viokase. For the sake of completeness, I should mention that digestive enzymes of all sorts are sold over ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver La tendance de croissance solide d'Axcan Pharma se poursuit, l'exercic... - Nov 29, 2007 Axcan a complété son programme d'essai clinique et déposé les données CFC (chimie, fabrication, contrôle) requise pour sa NDA sur ULTRASE et soumis la NDA ... marketwire.com No more pig virus tests for Solvay drug-US FDA panel - Dec 3, 2008 Other products include KV Pharmaceutical Co (KVa.N) unit Ethex Corp's Pangestyme and privately-held Axcan Pharma Inc's Ultrase, among others. Continued... Reuters Strong Start for Axcan Pharma's Fiscal 2007, With Record Revenue of … - Feb 8, 2007 Axcan is currently advancing the completion of the New Drug Application ("NDA") of ULTRASE and VIOKASE, and is on track to meet the deadline for NDA ... ccnmatthews.com Médicos e Idec: 50% dos pacientes não podem comprar remédios - Dec 9, 2006 A secretaria de saúde do Rio Grande do Sul informou que foram comprados 120 mil comprimidos do remédio Ultrase-MT12. Já a secretaria de Saúde de São Paulo ... O Globo Q1 2007 AXCAN PHARMA INC Earnings Conference Call - Part 2. - Feb 9, 2007 We did not increase the prices on ULTRASE. The price increases were in the 4 to ... Yet when we're looking at the commentary regarding ULTRASE and CARAFATE ... Free with registration - America's Intelligence Wire - AccessMyLibrary.com Beckstrand v. Electronic Arts Group Long Term Disability Insurance... - Oct 20, 2006 He documented his current medications including Agenerase, Epivir, Zerit, Sustiva, Norvir, Diflucan, Ultrase, Celexa, Acyclovir, and Bactrim." AR0213-0214. ... $2.95 - U.S. District Court, Eastern District... - VersusLaw Q1 2005 AXCAN PHARMA INC Earnings Conference Call - Final. - Feb 14, 2005 And looking through our prescription growth, we were encouraged by the fact that our new prescriptions on Ultrase, as of the end of December, ... Free with registration - Fair Disclosure Wire - AccessMyLibrary.com MANY WAYS TO HELP EASE PANCREATITIS - Oct 22, 2008 Prescription brands include Creon, Ultrase or Pancrease, or you can buy weaker versions such as Lypo Gold or Ultra Pancreatin at the health-food store. ... Pay-Per-View - South Florida Sun - Sentinel - ProQuest Archiver Izgredi v Italiji - Nov 12, 2007 DomaÄ?i zvezdnik Doni je v sedmi minuti tekme skuÅ¡al pomiriti ultrase na tribuni, a neuspeÅ¡no. Kasneje je pojasnil, da so mu povedali, da nameravajo vdreti ... Vest How to take Pancrelipase from Consumer Reports Health. - Jan 7, 2006 If you are taking Ultrase® brand capsules, tell your doctor if you are allergic to simethicone. tell your doctor and pharmacist what prescription and ... consumerreports.org Un début d'exercice 2007 solide pour Axcan Pharma avec des produits … - Feb 8, 2007 En avril 2004, la FDA a dûment avisé les fabricants de produits traitant l'insuffisance pancréatique que ces médicaments, qui incluent ULTRASE et VIOKASE, ... ccnmatthews.com Haider skozi Freuda - Oct 30, 2008 Za vse te "ultrase", predvsem pa za Fritzla in Haiderja, bi se dalo reÄ?i, da so normalen proizvod psihopatoloÅ¡ke matere. Medtem ko je bila Fritzlova mati ... VeÄ?er - VeÄ?er Bunderla odloÄ?il derbi v AjdovÅ¡Ä?ini - Apr 30, 2008 Moram priznati, da si (na žalost) zelo blizu resnice, Ä?eprav sama ne paÅ¡em ne med ravbarje, ne med ultrase. :). ÄŒe želite komentirati, morate biti ... SiOL.net TPG to Buy Canada's Axcan Pharma for $1.3 Billion - Nov 29, 2007 Axcan may benefit next year from increased sales of Ultrase, an enzyme-replacement therapy for the pancreas, said Laurence Rulleau, an analyst at Blackmont ... Bloomberg MMC RTV Slovenija - prvi multimedijski portal - Aug 10, 2008 Meni se je PeÄ?eÄ?nik zameril,ko je z Hlastecem zaÄ?el kovati naÄ?rte o navijaÅ¡kem zakonu s katerim so želeli in Å¡e želijo omejiti ultrase,Å¡e teh malo kar jih ... RTV Slovenija Press Release: Bellwether Report.com is Tracking Axcan Pharma Inc. - ... - Sep 21, 2006 The company's top seller is ULTRASE, which targets pancreatic problems related to cystic fibrosis. Axcan primarily markets its prescription drugs directly ... Pay-Per-View - M2 Presswire - HighBeam Research Axcan announces record revenue of $70.6 million for the first quarter... - Feb 9, 2006 Additional studies on ULTRASE are in process and anticipated to be completed and submitted along with other clinical and CMC data in the form of a New Drug ... $4.95 - PR Newswire - ECNext Merger and Acquisition Scenario - Feb 9, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Fudbalski huligani divljaju po Rimu, povreÄ‘eno 20 policajaca - Nov 11, 2007 Juventini su pozvali u pomoć policiju, koja je ispalila nekoliko hitaca u želji da obuzda ultrase iz Rima, ali je tom prilikom usmrćen 26-godiÅ¡nji Gabrijele ... Блиц - Блиц Policajac ubio navijaÄ?a Lacija - Nov 11, 2007 Juventini su pozvali u pomoć policiju, koja je ispalila nekoliko hitaca u želji da obuzda ultrase iz Rima, ali je tom prilikom usmrćen 26-godiÅ¡nji Gabriele ... B92 Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere How to take Miglitol from Consumer Reports Health. - Jan 5, 2007 ...digestive enzymes (Viokase, Pancrease, or Ultrase), digoxin (Lanoxin), propranolol (Inderal), ranitidine (Zantac), and vitamins. ... consumerreports.org Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Axcan Pharma With Record Revenue in the Third Quarter. - Aug 10, 2007 ..."We also recently completed the submission of our New Drug Application (NDA) for ULTRASE, which increases our confidence in being in a position to be one of ... $4.95 - M2 Presswire - ECNext Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Jan 26, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 15, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 16, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 23, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere <P>This article has been removed and is no longer available.</P> | … - Jun 21, 2007 Article: Axcan Pharma Submits CMC Portion of its New Drug Application for ULTRASE and is Granted Fast Track Status. Article from:: Canadian Corporate News ... Pay-Per-View - Canadian Corporate News - HighBeam Research Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 23, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 8, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 8, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Mar 22, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere Merger and Acquisition Scenario - Feb 23, 2008 During the fiscal year ended September 30, 2007 (fiscal 2007), the Company?s products included ULTRASE, CANASA, URSO 250/URSO FORTE, PYLERA and CARAFATE in ... $250.00 - Revere Reports - Revere <P>This article has been removed and is no longer available.</P> | … - Aug 2, 2007 Article: Axcan Pharma Submits Complete New Drug Application for ULTRASE. Article from:: Canadian Corporate News; Article date:: January 1, 0001 ... Pay-Per-View - Canadian Corporate News - HighBeam Research Brand Names/Synonyms: Ultrase is also known by the following brand names and/or synonymsPancreatic alpha-amylase precursor;PA;1,4-alpha-D- glucan glucanohydrolase; Pancrease (Ortho-McNeil); Cotazym (Organon); Ku-Zyme (Koichi); Ultrase (Axcan Scandipharm); Zymase (Organon) Drug Category: Ultrase is categorized under the following by the FDA: Enzyme replacement; enzymes (44:00.00) Dosage Forms: TABLET Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Not Available |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |